PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24599591-5 2014 We identify several hundred genes, the expression of which is correlated with levodopa dose, many of which are under the control of activator protein-1 and ERK signaling. Levodopa 78-86 mitogen-activated protein kinase 1 Homo sapiens 156-159 22709943-8 2012 Inhibitors of the ERK signaling pathway, which plays an important role in the development of l-DOPA-induced dyskinesia (LID), have been shown to attenuate this condition in animal models. Levodopa 93-99 mitogen-activated protein kinase 1 Homo sapiens 18-21 22753408-5 2012 These studies demonstrate that, in D1R-expressing MSNs, l-DOPA-induced activation of ERK and mTORC1 requires DARPP-32 and indicates the importance of the cAMP/DARPP-32 signaling cascade in dyskinesia. Levodopa 56-62 mitogen-activated protein kinase 1 Homo sapiens 85-88 35378500-11 2022 Western studies suggest that L-Dopa+IGF-1 modulates its effects via Akt/ERK dependent pathway. Levodopa 29-35 mitogen-activated protein kinase 1 Homo sapiens 72-75 18410512-4 2008 In the primate model, which closely resembles human LDID, we observed that chronic levodopa and the appearance of LDID was associated with marked deacetylation of histone H4, hyperacetylation and dephosphorylation of histone H3, and enhancement of the phosphorylation of extracellular signal-regulated kinase (ERK). Levodopa 83-91 mitogen-activated protein kinase 1 Homo sapiens 271-308 18410512-4 2008 In the primate model, which closely resembles human LDID, we observed that chronic levodopa and the appearance of LDID was associated with marked deacetylation of histone H4, hyperacetylation and dephosphorylation of histone H3, and enhancement of the phosphorylation of extracellular signal-regulated kinase (ERK). Levodopa 83-91 mitogen-activated protein kinase 1 Homo sapiens 310-313 15686961-0 2005 L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Levodopa 0-6 mitogen-activated protein kinase 1 Homo sapiens 93-96 15686961-7 2005 Changes in arrestin and GRK expression in the MPTP group were accompanied by enhanced ERK activation and elevated total ERK expression, which were also reversed by L-DOPA. Levodopa 164-170 mitogen-activated protein kinase 1 Homo sapiens 86-89 15686961-7 2005 Changes in arrestin and GRK expression in the MPTP group were accompanied by enhanced ERK activation and elevated total ERK expression, which were also reversed by L-DOPA. Levodopa 164-170 mitogen-activated protein kinase 1 Homo sapiens 120-123 23209759-9 2012 Increased homocysteine by levodopa led to increased apoptosis of NPCs through the NMDA receptor-dependent the extracellular signal-regulated kinase (ERK) signaling pathways. Levodopa 26-34 mitogen-activated protein kinase 1 Homo sapiens 110-147 23209759-9 2012 Increased homocysteine by levodopa led to increased apoptosis of NPCs through the NMDA receptor-dependent the extracellular signal-regulated kinase (ERK) signaling pathways. Levodopa 26-34 mitogen-activated protein kinase 1 Homo sapiens 149-152 23209759-12 2012 Our present study demonstrated that increased homocysteine by levodopa has a detrimental effect on neurogenesis through NMDA receptor-mediated ERK signaling pathway. Levodopa 62-70 mitogen-activated protein kinase 1 Homo sapiens 143-146 22131969-3 2011 However, abnormal Ras-ERK signaling has also been linked to a number of neuropsychiatric conditions, including mental retardation syndromes ("RASopathies"), drug addiction, and l-DOPA induced dyskinesia (LID). Levodopa 177-183 mitogen-activated protein kinase 1 Homo sapiens 22-25 20808799-1 2010 BACKGROUND: In rodents, the development of dyskinesia produced by L-DOPA in the dopamine-depleted striatum occurs in response to increased dopamine D1 receptor-mediated activation of the cAMP - protein kinase A and of the Ras-extracellular signal-regulated kinase (ERK) signalling pathways. Levodopa 66-72 mitogen-activated protein kinase 1 Homo sapiens 222-263 20808799-1 2010 BACKGROUND: In rodents, the development of dyskinesia produced by L-DOPA in the dopamine-depleted striatum occurs in response to increased dopamine D1 receptor-mediated activation of the cAMP - protein kinase A and of the Ras-extracellular signal-regulated kinase (ERK) signalling pathways. Levodopa 66-72 mitogen-activated protein kinase 1 Homo sapiens 265-268 20808799-5 2010 In contrast, phosphorylation of ERK and S6 was enhanced preferentially after acute L-DOPA administration and decreased during the course of chronic treatment. Levodopa 83-89 mitogen-activated protein kinase 1 Homo sapiens 32-35 20808799-6 2010 CONCLUSION: Dysregulation of cAMP signalling is maintained during the course of chronic L-DOPA administration, while abnormal ERK signalling peaks during the initial phase of L-DOPA treatment and decreases following prolonged exposure. Levodopa 175-181 mitogen-activated protein kinase 1 Homo sapiens 126-129 29492662-4 2018 Experimental animal models of PD identified in DA D1/ERK-signaling pathway aberrant activation, occurring in striatal projection neurons, coupled with structural spines abnormalities, the molecular and neuronal basis of L-DOPA-induced dyskinesia (LIDs) occurrence. Levodopa 220-226 mitogen-activated protein kinase 1 Homo sapiens 53-56 32426479-6 2020 Besides acting as a GEF for Ras homolog enriched in the brain (Rheb), the activator of the mammalian target of rapamycin kinase (mTOR), RasGRP1 promotes l-DOPA-induced extracellular signal-regulated kinase (ERK) and the mTOR signaling in the striatum. Levodopa 153-159 mitogen-activated protein kinase 1 Homo sapiens 168-205 32426479-6 2020 Besides acting as a GEF for Ras homolog enriched in the brain (Rheb), the activator of the mammalian target of rapamycin kinase (mTOR), RasGRP1 promotes l-DOPA-induced extracellular signal-regulated kinase (ERK) and the mTOR signaling in the striatum. Levodopa 153-159 mitogen-activated protein kinase 1 Homo sapiens 207-210